Express Pharma

Novartis arthritis drug fails to prove it is significantly better than rival

Novartis said Cosentyx, when used to treat active psoriatic arthritis, "narrowly missed statistical significance for superiority" versus Humira, a drug made by AbbVie

0 281

A clinical trial of Novartis’s Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said.

Novartis said Cosentyx, when used to treat active psoriatic arthritis, “narrowly missed statistical significance for superiority” versus Humira, a drug made by AbbVie.

“While Cosentyx narrowly missed statistical significance for superiority…. it showed numerically higher results versus Humira,” Novartis said following the results of a head-to-head trial.

Psoriatic arthritis, an inflammatory disease affecting the joints, is a condition which affects around 50 million people worldwide.

This week US regulators halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety concerns.

- Advertisement -

Leave A Reply

Your email address will not be published.